Classical psychedelics like psilocybin, LSD, and DMT may serve not only as treatments for mental health disorders but also as agents of cellular and psychological rejuvenation. Drawing from preclinical and early human studies, the framework proposes that these compounds modulate aging pathways including neuroplasticity, inflammation, mitochondrial function, and telomere dynamics. They appear to repair dysregulated brain states and engage mechanisms linked to resilience, longevity, and cognitive preservation. Psychological benefits—such as increased openness, emotional flexibility, and stress reduction—are supported by durable shifts in brain network dynamics via 5-HT₂A receptor activation and increased neural entropy. Integration may convert these neurobiological changes into lasting lifestyle improvements, positioning psychedelics as tools for proactive health optimization.
A simple endogenous tryptamine can profoundly alter perception and self-modeling. The Birth Echo Hypothesis proposes that during a narrow perinatal window around delivery, a convergence of stress, sensory novelty, and neuromodulators biases encoding of high-salience sensorimotor templates. In adulthood, exogenous DMT may reconfigure brain dynamics via 5-HT2A and sigma-1 receptors, making these preverbal templates accessible as archetypal, emotionally intense, synesthetic content. DMT is framed as a co-modulator within an evolved perinatal regulatory ensemble. Testable predictions include adult DMT phenomenology showing perinatal-consistent motifs, neonatal EEG/fMRI state-space similarity to adult DMT states, and peri-parturient biospecimens revealing DMT-pathway marker co-variation. The hypothesis reframes psychedelic phenomenology as structural re-expression of early sensorimotor templates.